News
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant
Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...
Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.
Auto supplier blamed for polluting Ann Arbor’s water supply is allowing polluted stormwater into the Huron River, state ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results